// src/lib/frozenResponses.ts

export const FROZEN_RESPONSES: Record<string, any> = {
  "did dupilumab receive fda approval for asthma before chronic rhinosinusitis": {
  "answer": "The sequence of FDA approvals for Dupilumab indicates that its approval for asthma occurred after its approval for chronic rhinosinusitis. This suggests that the regulatory pathway for chronic rhinosinusitis was prioritized, possibly due to the pressing need for effective treatments in that area, which was supported by clinical evidence demonstrating significant benefits for patients suffering from chronic rhinosinusitis [1]. Furthermore, the approval timeline reflects a strategic approach by the manufacturers to address the most urgent health concerns first, which can often influence the order of approvals [2].\n\nAdditionally, the approval for chronic rhinosinusitis was based on a robust set of clinical trials that highlighted the drug's efficacy in managing symptoms and improving quality of life for patients. This foundational approval likely set the stage for subsequent applications for other indications, such as asthma, which may have required additional data to support its use in that context [1]. The regulatory decisions made in this case illustrate the complexities involved in drug approvals, where the urgency of treatment needs can dictate the order in which approvals are granted [2].",
  "overall_uncertainty": 0.87,
  "token_uncertainty": [
    { "token": "The", "score": 0.58 },
    { "token": "sequence", "score": 0.86 },
    { "token": "of", "score": 0.52 },
    { "token": "FDA", "score": 0.79 },
    { "token": "approvals", "score": 0.88 },
    { "token": "for", "score": 0.55 },
    { "token": "Dupilumab", "score": 0.91 },
    { "token": "indicates", "score": 0.83 },
    { "token": "that", "score": 0.49 },
    { "token": "its", "score": 0.47 },
    { "token": "approval", "score": 0.87 },
    { "token": "asthma", "score": 0.84 },
    { "token": "occurred", "score": 0.81 },
    { "token": "after", "score": 0.53 },
    { "token": "chronic", "score": 0.78 },
    { "token": "rhinosinusitis", "score": 0.90 },
    { "token": "This", "score": 0.60 },
    { "token": "suggests", "score": 0.82 },
    { "token": "the", "score": 0.56 },
    { "token": "regulatory", "score": 0.85 },
    { "token": "pathway", "score": 0.84 },
    { "token": "was", "score": 0.51 },
    { "token": "prioritized", "score": 0.80 },
    { "token": "possibly", "score": 0.64 },
    { "token": "due", "score": 0.57 },
    { "token": "to", "score": 0.50 },
    { "token": "the", "score": 0.54 },
    { "token": "pressing", "score": 0.77 },
    { "token": "need", "score": 0.76 },
    { "token": "for", "score": 0.55 },
    { "token": "effective", "score": 0.79 },
    { "token": "treatments", "score": 0.82 },
    { "token": "in", "score": 0.48 },
    { "token": "that", "score": 0.50 },
    { "token": "area", "score": 0.70 },
    { "token": "which", "score": 0.58 },
    { "token": "was", "score": 0.52 },
    { "token": "supported", "score": 0.74 },
    { "token": "by", "score": 0.46 },
    { "token": "clinical", "score": 0.80 },
    { "token": "evidence", "score": 0.83 },
    { "token": "demonstrating", "score": 0.79 },
    { "token": "significant", "score": 0.75 },
    { "token": "benefits", "score": 0.78 },
    { "token": "for", "score": 0.55 },
    { "token": "patients", "score": 0.73 },
    { "token": "suffering", "score": 0.76 },
    { "token": "from", "score": 0.54 },
    { "token": "chronic", "score": 0.77 },
    { "token": "rhinosinusitis", "score": 0.90 },
    { "token": "[1]", "score": 0.63 },
    { "token": "Furthermore", "score": 0.74 },
    { "token": ",", "score": 0.44 },
    { "token": "the", "score": 0.57 },
    { "token": "approval", "score": 0.86 },
    { "token": "timeline", "score": 0.82 },
    { "token": "reflects", "score": 0.77 },
    { "token": "a", "score": 0.46 },
    { "token": "strategic", "score": 0.81 },
    { "token": "approach", "score": 0.78 },
    { "token": "by", "score": 0.49 },
    { "token": "the", "score": 0.56 },
    { "token": "manufacturers", "score": 0.80 },
    { "token": "to", "score": 0.50 },
    { "token": "address", "score": 0.74 },
    { "token": "the", "score": 0.55 },
    { "token": "most", "score": 0.62 },
    { "token": "urgent", "score": 0.76 },
    { "token": "health", "score": 0.73 },
    { "token": "concerns", "score": 0.79 },
    { "token": "first", "score": 0.62 },
    { "token": ",", "score": 0.45 },
    { "token": "which", "score": 0.58 },
    { "token": "can", "score": 0.54 },
    { "token": "often", "score": 0.61 },
    { "token": "influence", "score": 0.74 },
    { "token": "the", "score": 0.56 },
    { "token": "order", "score": 0.70 },
    { "token": "of", "score": 0.53 },
    { "token": "approvals", "score": 0.88 },
    { "token": "[2]", "score": 0.64 },
    { "token": "Additionally", "score": 0.73 },
    { "token": ",", "score": 0.43 },
    { "token": "the", "score": 0.57 },
    { "token": "approval", "score": 0.86 },
    { "token": "for", "score": 0.56 },
    { "token": "chronic", "score": 0.78 },
    { "token": "rhinosinusitis", "score": 0.90 },
    { "token": "was", "score": 0.52 },
    { "token": "based", "score": 0.72 },
    { "token": "on", "score": 0.51 },
    { "token": "a", "score": 0.45 },
    { "token": "robust", "score": 0.74 },
    { "token": "set", "score": 0.67 },
    { "token": "of", "score": 0.54 },
    { "token": "clinical", "score": 0.81 },
    { "token": "trials", "score": 0.78 },
    { "token": "that", "score": 0.50 },
    { "token": "highlighted", "score": 0.73 },
    { "token": "the", "score": 0.56 },
    { "token": "drug's", "score": 0.70 },
    { "token": "efficacy", "score": 0.79 },
    { "token": "in", "score": 0.49 },
    { "token": "managing", "score": 0.74 },
    { "token": "symptoms", "score": 0.78 },
    { "token": "and", "score": 0.55 },
    { "token": "improving", "score": 0.76 },
    { "token": "quality", "score": 0.75 },
    { "token": "of", "score": 0.53 },
    { "token": "life", "score": 0.74 },
    { "token": "for", "score": 0.55 },
    { "token": "patients", "score": 0.72 },
    { "token": "This", "score": 0.61 },
    { "token": "foundational", "score": 0.77 },
    { "token": "approval", "score": 0.87 },
    { "token": "likely", "score": 0.64 },
    { "token": "set", "score": 0.67 },
    { "token": "the", "score": 0.56 },
    { "token": "stage", "score": 0.71 },
    { "token": "for", "score": 0.56 },
    { "token": "subsequent", "score": 0.78 },
    { "token": "applications", "score": 0.80 },
    { "token": "for", "score": 0.55 },
    { "token": "other", "score": 0.62 },
    { "token": "indications", "score": 0.79 },
    { "token": ",", "score": 0.44 },
    { "token": "such", "score": 0.60 },
    { "token": "as", "score": 0.52 },
    { "token": "asthma", "score": 0.84 },
    { "token": ",", "score": 0.44 },
    { "token": "which", "score": 0.58 },
    { "token": "may", "score": 0.54 },
    { "token": "have", "score": 0.53 },
    { "token": "required", "score": 0.72 },
    { "token": "additional", "score": 0.75 },
    { "token": "data", "score": 0.70 },
    { "token": "to", "score": 0.50 },
    { "token": "support", "score": 0.73 },
    { "token": "its", "score": 0.49 },
    { "token": "use", "score": 0.67 },
    { "token": "in", "score": 0.49 },
    { "token": "that", "score": 0.50 },
    { "token": "context", "score": 0.69 },
    { "token": "[1]", "score": 0.63 },
    { "token": "The", "score": 0.58 },
    { "token": "regulatory", "score": 0.85 },
    { "token": "decisions", "score": 0.80 },
    { "token": "made", "score": 0.70 },
    { "token": "in", "score": 0.49 },
    { "token": "this", "score": 0.56 },
    { "token": "case", "score": 0.67 },
    { "token": "illustrate", "score": 0.74 },
    { "token": "the", "score": 0.56 },
    { "token": "complexities", "score": 0.79 },
    { "token": "involved", "score": 0.73 },
    { "token": "in", "score": 0.49 },
    { "token": "drug", "score": 0.70 },
    { "token": "approvals", "score": 0.88 },
    { "token": ",", "score": 0.44 },
    { "token": "where", "score": 0.60 },
    { "token": "the", "score": 0.56 },
    { "token": "urgency", "score": 0.76 },
    { "token": "of", "score": 0.53 },
    { "token": "treatment", "score": 0.77 },
    { "token": "needs", "score": 0.73 },
    { "token": "can", "score": 0.54 },
    { "token": "dictate", "score": 0.74 },
    { "token": "the", "score": 0.56 },
    { "token": "order", "score": 0.70 },
    { "token": "in", "score": 0.49 },
    { "token": "which", "score": 0.58 },
    { "token": "approvals", "score": 0.88 },
    { "token": "are", "score": 0.52 },
    { "token": "granted", "score": 0.72 },
    { "token": "[2]", "score": 0.64 }
  ],
  "central_claim": "Dupilumab did not receive FDA approval for asthma before chronic rhinosinusitis.",
  "relations": [
  {
    "source": "The regulatory pathway for chronic rhinosinusitis was prioritized, possibly due to the pressing need for effective treatments in that area, which was supported by clinical evidence demonstrating significant benefits for patients suffering from chronic rhinosinusitis [1].",
    "type": "SUPPORTS",
    "target": "central_claim",
    "score": 0.8,
    "explanation": "This supports the claim because it highlights the prioritization of chronic rhinosinusitis over asthma in the approval process.",
    "relation_links": [
      {
        "url": "https://www.mayoclinic.org/drugs-supplements/dupilumab-subcutaneous-route/description/drg-20406153",
        "title": "Mayo Clinic",
        "summary": "Mayo Clinic provides comprehensive information on various medical conditions, including treatment options and drug approvals."
      }
    ]
  },
  {
    "source": "The approval timeline reflects a strategic approach by the manufacturers to address the most urgent health concerns first, which can often influence the order of approvals [2].",
    "type": "SUPPORTS",
    "target": "central_claim",
    "score": 0.82,
    "explanation": "This supports the claim because it indicates that the approval for chronic rhinosinusitis was a strategic decision based on urgency.",
    "relation_links": [
      {
        "url": "https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-us-first-new-targeted-therapy-over",
        "title": "Regeneron",
        "summary": "The CDC offers insights into public health priorities and the impact of various treatments on health outcomes."
      }
    ]
  },
  {
    "source": "This foundational approval likely set the stage for subsequent applications for other indications, such as asthma, which may have required additional data to support its use in that context [1].",
    "type": "ATTACKS",
    "target": "central_claim",
    "score": 0.47,
    "explanation": "This attacks the claim because it introduces doubt about the necessity and urgency of the asthma approval compared to chronic rhinosinusitis.",
    "relation_links": [
      {
        "url": "https://medlineplus.gov/druginfo/meds/a617021.html",
        "title": "MedlinePlus",
        "summary": "MedlinePlus provides reliable information on health conditions, medications, and the approval processes for various treatments."
      }
    ]
  },
  {
    "source": "The regulatory decisions made in this case illustrate the complexities involved in drug approvals, where the urgency of treatment needs can dictate the order in which approvals are granted [2].",
    "type": "ATTACKS",
    "target": "central_claim",
    "score": 0.53,
    "explanation": "This attacks the claim because it suggests that the approval process is not always linear and can be influenced by multiple factors.",
    "relation_links": [
      {
        "url": "https://www.health.harvard.edu/blog/harvard-health-ad-watch-a-new-injection-treatment-for-eczema-202209272824",
        "title": "Harvard Health",
        "summary": "Harvard Health discusses various health topics, including the complexities of drug approvals and their implications for treatment."
      }
    ]
  }
],

  "links_paragraph": [
    {
      "url": "https://www.mayoclinic.org/drugs-supplements/dupilumab-subcutaneous-route/description/drg-20406153",
      "title": "Mayo Clinic",
      "summary": "Mayo Clinic provides comprehensive information on various medical conditions, including treatment options and drug approvals."
    },
    {
      "url": "https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-us-first-new-targeted-therapy-over",
      "title": "Regeneron",
      "summary": "Regeneron offers insights into public health priorities and the impact of various treatments on health outcomes."
    },
    {
      "url": "https://medlineplus.gov/druginfo/meds/a617021.html",
      "title": "MedlinePlus",
      "summary": "MedlinePlus provides reliable information on health conditions, medications, and the approval processes for various treatments."
    },
    {
      "url": "https://www.health.harvard.edu/blog/harvard-health-ad-watch-a-new-injection-treatment-for-eczema-202209272824",
      "title": "Harvard Health",
      "summary": "Harvard Health discusses various health topics, including the complexities of drug approvals and their implications for treatment."
    }
  ]
},

  "is there more antihistamine in benadryl than rhinocort": {
  "answer": "The analysis suggests that Benadryl does not contain more antihistamine than Rhinocort based on their distinct pharmacological compositions. Rhinocort, primarily formulated as a corticosteroid nasal spray, exerts downstream antihistamine-like effects through anti-inflammatory mechanisms that are more concentrated and targeted for allergic reactions than the antihistamine present in Benadryl. This specialized formulation in Rhinocort allows it to deliver a higher effective dose of antihistamine activity despite Benadryl's reputation as an antihistamine medication [1].\n\nHowever, one could argue that the difference in delivery methods and drug classes complicates direct comparisons of antihistamine content. Benadryl, an oral antihistamine, contains a different class of antihistamine agents that act systemically but at lower concentrations compared to Rhinocort's localized and potent antihistamine effect. This raises a concern that simply measuring total antihistamine content without considering pharmacodynamics and administration routes may misrepresent the actual antihistamine potency, supporting the conclusion that Benadryl does not have more antihistamine than Rhinocort [2].",
  "overall_uncertainty": 0.75,
  "token_uncertainty": [
  { "token": "The", "score": 0.52 },
  { "token": "analysis", "score": 0.74 },
  { "token": "suggests", "score": 0.83 },
  { "token": "that", "score": 0.55 },
  { "token": "Benadryl", "score": 0.86 },
  { "token": "does", "score": 0.58 },
  { "token": "not", "score": 0.57 },
  { "token": "contain", "score": 0.78 },
  { "token": "more", "score": 0.62 },
  { "token": "antihistamine", "score": 0.88 },
  { "token": "than", "score": 0.54 },
  { "token": "Rhinocort", "score": 0.87 },
  { "token": "based", "score": 0.70 },
  { "token": "on", "score": 0.50 },
  { "token": "their", "score": 0.56 },
  { "token": "distinct", "score": 0.77 },
  { "token": "pharmacological", "score": 0.90 },
  { "token": "compositions", "score": 0.82 },
  { "token": ".", "score": 0.20 },

  { "token": "Rhinocort", "score": 0.87 },
  { "token": "primarily", "score": 0.72 },
  { "token": "formulated", "score": 0.74 },
  { "token": "as", "score": 0.50 },
  { "token": "a", "score": 0.45 },
  { "token": "corticosteroid", "score": 0.90 },
  { "token": "nasal", "score": 0.72 },
  { "token": "spray", "score": 0.70 },
  { "token": ",", "score": 0.20 },
  { "token": "incorporates", "score": 0.78 },
  { "token": "a", "score": 0.46 },
  { "token": "unique", "score": 0.71 },
  { "token": "antihistamine", "score": 0.88 },
  { "token": "component", "score": 0.69 },
  { "token": "that", "score": 0.55 },
  { "token": "is", "score": 0.52 },
  { "token": "more", "score": 0.62 },
  { "token": "concentrated", "score": 0.80 },
  { "token": "and", "score": 0.50 },
  { "token": "targeted", "score": 0.76 },
  { "token": "for", "score": 0.50 },
  { "token": "allergic", "score": 0.72 },
  { "token": "reactions", "score": 0.73 },
  { "token": "than", "score": 0.54 },
  { "token": "the", "score": 0.52 },
  { "token": "antihistamine", "score": 0.88 },
  { "token": "present", "score": 0.70 },
  { "token": "in", "score": 0.48 },
  { "token": "Benadryl", "score": 0.86 },
  { "token": ".", "score": 0.20 },

  { "token": "This", "score": 0.58 },
  { "token": "specialized", "score": 0.78 },
  { "token": "formulation", "score": 0.76 },
  { "token": "in", "score": 0.48 },
  { "token": "Rhinocort", "score": 0.87 },
  { "token": "allows", "score": 0.68 },
  { "token": "it", "score": 0.50 },
  { "token": "to", "score": 0.49 },
  { "token": "deliver", "score": 0.74 },
  { "token": "a", "score": 0.45 },
  { "token": "higher", "score": 0.70 },
  { "token": "effective", "score": 0.72 },
  { "token": "dose", "score": 0.69 },
  { "token": "of", "score": 0.50 },
  { "token": "antihistamine", "score": 0.88 },
  { "token": "activity", "score": 0.71 },
  { "token": "despite", "score": 0.72 },
  { "token": "Benadryl's", "score": 0.80 },
  { "token": "reputation", "score": 0.74 },
  { "token": "as", "score": 0.50 },
  { "token": "an", "score": 0.48 },
  { "token": "antihistamine", "score": 0.88 },
  { "token": "medication", "score": 0.70 },
  { "token": ".", "score": 0.20 },

  { "token": "However", "score": 0.78 },
  { "token": ",", "score": 0.20 },
  { "token": "one", "score": 0.58 },
  { "token": "could", "score": 0.66 },
  { "token": "argue", "score": 0.78 },
  { "token": "that", "score": 0.55 },
  { "token": "the", "score": 0.52 },
  { "token": "difference", "score": 0.74 },
  { "token": "in", "score": 0.48 },
  { "token": "delivery", "score": 0.76 },
  { "token": "methods", "score": 0.72 },
  { "token": "and", "score": 0.50 },
  { "token": "drug", "score": 0.68 },
  { "token": "classes", "score": 0.72 },
  { "token": "complicates", "score": 0.86 },
  { "token": "direct", "score": 0.70 },
  { "token": "comparisons", "score": 0.74 },
  { "token": "of", "score": 0.50 },
  { "token": "antihistamine", "score": 0.88 },
  { "token": "content", "score": 0.72 },
  { "token": ".", "score": 0.20 },

  { "token": "Benadryl", "score": 0.86 },
  { "token": ",", "score": 0.20 },
  { "token": "an", "score": 0.48 },
  { "token": "oral", "score": 0.66 },
  { "token": "antihistamine", "score": 0.88 },
  { "token": ",", "score": 0.20 },
  { "token": "contains", "score": 0.74 },
  { "token": "a", "score": 0.45 },
  { "token": "different", "score": 0.69 },
  { "token": "class", "score": 0.70 },
  { "token": "of", "score": 0.50 },
  { "token": "antihistamine", "score": 0.88 },
  { "token": "agents", "score": 0.72 },
  { "token": "that", "score": 0.55 },
  { "token": "act", "score": 0.68 },
  { "token": "systemically", "score": 0.82 },
  { "token": "but", "score": 0.50 },
  { "token": "at", "score": 0.48 },
  { "token": "lower", "score": 0.66 },
  { "token": "concentrations", "score": 0.82 },
  { "token": "compared", "score": 0.72 },
  { "token": "to", "score": 0.49 },
  { "token": "Rhinocort's", "score": 0.82 },
  { "token": "localized", "score": 0.76 },
  { "token": "and", "score": 0.50 },
  { "token": "potent", "score": 0.74 },
  { "token": "antihistamine", "score": 0.88 },
  { "token": "effect", "score": 0.70 },
  { "token": ".", "score": 0.20 },

  { "token": "This", "score": 0.58 },
  { "token": "raises", "score": 0.78 },
  { "token": "a", "score": 0.45 },
  { "token": "concern", "score": 0.78 },
  { "token": "that", "score": 0.55 },
  { "token": "simply", "score": 0.66 },
  { "token": "measuring", "score": 0.72 },
  { "token": "total", "score": 0.69 },
  { "token": "antihistamine", "score": 0.88 },
  { "token": "content", "score": 0.72 },
  { "token": "without", "score": 0.62 },
  { "token": "considering", "score": 0.74 },
  { "token": "pharmacodynamics", "score": 0.90 },
  { "token": "and", "score": 0.50 },
  { "token": "administration", "score": 0.74 },
  { "token": "routes", "score": 0.72 },
  { "token": "may", "score": 0.58 },
  { "token": "misrepresent", "score": 0.88 },
  { "token": "the", "score": 0.52 },
  { "token": "actual", "score": 0.70 },
  { "token": "antihistamine", "score": 0.88 },
  { "token": "potency", "score": 0.74 },
  { "token": ",", "score": 0.20 },
  { "token": "supporting", "score": 0.80 },
  { "token": "the", "score": 0.52 },
  { "token": "conclusion", "score": 0.74 },
  { "token": "that", "score": 0.55 },
  { "token": "Benadryl", "score": 0.86 },
  { "token": "does", "score": 0.58 },
  { "token": "not", "score": 0.57 },
  { "token": "have", "score": 0.58 },
  { "token": "more", "score": 0.62 },
  { "token": "antihistamine", "score": 0.88 },
  { "token": "than", "score": 0.54 },
  { "token": "Rhinocort", "score": 0.87 },
  { "token": ".", "score": 0.20 }
]
,
  "central_claim": "Benadryl does not contain more antihistamine than Rhinocort",
  "relations": [
  {
    "source": "Rhinocort’s specialized formulation allows it to deliver a higher effective dose of antihistamine activity despite Benadryl’s reputation as an antihistamine medication [1].",
    "type": "SUPPORTS",
    "target": "central_claim",
    "score": 0.95,
    "explanation": "This supports the claim because Rhinocort's antihistamine concentration is higher than Benadryl's.",
    "relation_links": [
      {
        "url": "https://medlineplus.gov/allergy.html",
        "title": "Pharmacological profiles of nasal corticosteroids and antihistamines",
        "summary": "This source details the pharmacological differences between nasal corticosteroids like Rhinocort and oral antihistamines like Benadryl."
      }
    ]
  },
  {
    "source": "Benadryl, an oral antihistamine, contains a different class of antihistamine agents that act systemically but at lower concentrations compared to Rhinocort’s localized and potent antihistamine effect [2].",
    "type": "SUPPORTS",
    "target": "central_claim",
    "score": 0.9,
    "explanation": "This supports the claim because Benadryl's antihistamine concentration is lower than Rhinocort's.",
    "relation_links": [
      {
        "url": "https://www.mayoclinic.org/diseases-conditions/allergies/in-depth/allergy-medications/art-20047403",
        "title": "Comparative analysis of antihistamine delivery methods",
        "summary": "This article compares the concentration and delivery of antihistamines in different drug formulations."
      }
    ]
  },
  {
    "source": "The difference in delivery methods and drug classes complicates direct comparisons of antihistamine content.",
    "type": "ATTACKS",
    "target": "central_claim",
    "score": 0.7,
    "explanation": "This attacks the claim because it highlights the complexity in comparing antihistamine content across different drug types.",
    "relation_links": []
  },
  {
    "source": "Simply measuring total antihistamine content without considering pharmacodynamics and administration routes may misrepresent the actual antihistamine potency [2].",
    "type": "ATTACKS",
    "target": "central_claim",
    "score": 0.65,
    "explanation": "This attacks the claim because it questions the validity of comparing antihistamine amounts without context.",
    "relation_links": []
  }
],

  "links_paragraph": [
    {
      "url": "https://medlineplus.gov/antihistamines.html",
      "title": "Pharmacological profiles of nasal corticosteroids and antihistamines",
      "summary": "This source details the pharmacological differences between nasal corticosteroids like Rhinocort and oral antihistamines like Benadryl."
    },
    {
      "url": "https://www.mayoclinic.org/diseases-conditions/allergies/in-depth/allergy-medications/art-20047403",
      "title": "Comparative analysis of antihistamine delivery methods",
      "summary": "This article compares the concentration and delivery of antihistamines in different drug formulations."
    }
  ]
},

  "is deep vein thrombosis a common side effect of ocella": {
  "answer": "Deep Vein Thrombosis (DVT) is a common side effect of Ocella due to its hormonal composition, which can increase blood coagulability and promote clot formation in susceptible individuals. The estrogen component in Ocella is known to elevate the risk of thrombotic events by altering the balance of clotting factors, making DVT a frequently observed adverse effect in patients using this medication [1]. This risk is particularly notable in women with additional predisposing factors such as obesity or prolonged immobility, which further compounds the likelihood of developing DVT while on Ocella therapy.\n\nClinical observations and pharmacological analyses have consistently demonstrated that Ocella's formulation contributes to a prothrombotic state, thereby increasing the incidence of DVT among its users compared to non-users [2]. The mechanism involves enhanced platelet aggregation and reduced fibrinolysis, which together facilitate venous clot formation. These findings underscore the importance of monitoring patients on Ocella for signs of DVT and considering risk factors before prescribing this medication [2].",
  "overall_uncertainty": 0.42,
  "token_uncertainty": [
  { "token": "Deep", "score": 0.78 },
  { "token": "Vein", "score": 0.74 },
  { "token": "Thrombosis", "score": 0.82 },
  { "token": "(", "score": 0.18 },
  { "token": "DVT", "score": 0.71 },
  { "token": ")", "score": 0.17 },
  { "token": "is", "score": 0.22 },
  { "token": "a", "score": 0.20 },
  { "token": "common", "score": 0.55 },
  { "token": "side", "score": 0.49 },
  { "token": "effect", "score": 0.52 },
  { "token": "of", "score": 0.21 },
  { "token": "Ocella", "score": 0.73 },
  { "token": "due", "score": 0.50 },
  { "token": "to", "score": 0.24 },
  { "token": "its", "score": 0.25 },
  { "token": "hormonal", "score": 0.60 },
  { "token": "composition", "score": 0.57 },
  { "token": ",", "score": 0.16 },
  { "token": "which", "score": 0.28 },
  { "token": "can", "score": 0.30 },
  { "token": "increase", "score": 0.58 },
  { "token": "blood", "score": 0.63 },
  { "token": "coagulability", "score": 0.77 },
  { "token": "and", "score": 0.23 },
  { "token": "promote", "score": 0.56 },
  { "token": "clot", "score": 0.69 },
  { "token": "formation", "score": 0.54 },
  { "token": "in", "score": 0.20 },
  { "token": "susceptible", "score": 0.61 },
  { "token": "individuals", "score": 0.57 },
  { "token": ".", "score": 0.15 },

  { "token": "The", "score": 0.24 },
  { "token": "estrogen", "score": 0.76 },
  { "token": "component", "score": 0.60 },
  { "token": "in", "score": 0.21 },
  { "token": "Ocella", "score": 0.72 },
  { "token": "is", "score": 0.23 },
  { "token": "known", "score": 0.52 },
  { "token": "to", "score": 0.25 },
  { "token": "elevate", "score": 0.58 },
  { "token": "the", "score": 0.22 },
  { "token": "risk", "score": 0.55 },
  { "token": "of", "score": 0.21 },
  { "token": "thrombotic", "score": 0.79 },
  { "token": "events", "score": 0.62 },
  { "token": "by", "score": 0.26 },
  { "token": "altering", "score": 0.57 },
  { "token": "the", "score": 0.22 },
  { "token": "balance", "score": 0.54 },
  { "token": "of", "score": 0.21 },
  { "token": "clotting", "score": 0.73 },
  { "token": "factors", "score": 0.61 },
  { "token": ",", "score": 0.16 },
  { "token": "making", "score": 0.52 },
  { "token": "DVT", "score": 0.70 },
  { "token": "a", "score": 0.20 },
  { "token": "frequently", "score": 0.56 },
  { "token": "observed", "score": 0.53 },
  { "token": "adverse", "score": 0.62 },
  { "token": "effect", "score": 0.51 },
  { "token": "in", "score": 0.20 },
  { "token": "patients", "score": 0.60 },
  { "token": "using", "score": 0.50 },
  { "token": "this", "score": 0.26 },
  { "token": "medication", "score": 0.63 },
  { "token": "[", "score": 0.18 },
  { "token": "1", "score": 0.24 },
  { "token": "]", "score": 0.19 },
  { "token": ".", "score": 0.15 },

  { "token": "This", "score": 0.27 },
  { "token": "risk", "score": 0.56 },
  { "token": "is", "score": 0.23 },
  { "token": "particularly", "score": 0.58 },
  { "token": "notable", "score": 0.53 },
  { "token": "in", "score": 0.21 },
  { "token": "women", "score": 0.62 },
  { "token": "with", "score": 0.30 },
  { "token": "additional", "score": 0.57 },
  { "token": "predisposing", "score": 0.77 },
  { "token": "factors", "score": 0.60 },
  { "token": "such", "score": 0.48 },
  { "token": "as", "score": 0.29 },
  { "token": "obesity", "score": 0.71 },
  { "token": "or", "score": 0.27 },
  { "token": "prolonged", "score": 0.56 },
  { "token": "immobility", "score": 0.74 },
  { "token": ",", "score": 0.16 },
  { "token": "which", "score": 0.29 },
  { "token": "further", "score": 0.53 },
  { "token": "compounds", "score": 0.55 },
  { "token": "the", "score": 0.22 },
  { "token": "likelihood", "score": 0.60 },
  { "token": "of", "score": 0.21 },
  { "token": "developing", "score": 0.56 },
  { "token": "DVT", "score": 0.69 },
  { "token": "while", "score": 0.30 },
  { "token": "on", "score": 0.22 },
  { "token": "Ocella", "score": 0.73 },
  { "token": "therapy", "score": 0.52 },
  { "token": ".", "score": 0.15 },

  { "token": "Clinical", "score": 0.62 },
  { "token": "observations", "score": 0.57 },
  { "token": "and", "score": 0.23 },
  { "token": "pharmacological", "score": 0.74 },
  { "token": "analyses", "score": 0.60 },
  { "token": "have", "score": 0.30 },
  { "token": "consistently", "score": 0.56 },
  { "token": "demonstrated", "score": 0.60 },
  { "token": "that", "score": 0.28 },
  { "token": "Ocella's", "score": 0.71 },
  { "token": "formulation", "score": 0.58 },
  { "token": "contributes", "score": 0.60 },
  { "token": "to", "score": 0.24 },
  { "token": "a", "score": 0.20 },
  { "token": "prothrombotic", "score": 0.78 },
  { "token": "state", "score": 0.55 },
  { "token": ",", "score": 0.16 },
  { "token": "thereby", "score": 0.50 },
  { "token": "increasing", "score": 0.58 },
  { "token": "the", "score": 0.22 },
  { "token": "incidence", "score": 0.60 },
  { "token": "of", "score": 0.21 },
  { "token": "DVT", "score": 0.70 },
  { "token": "among", "score": 0.52 },
  { "token": "its", "score": 0.25 },
  { "token": "users", "score": 0.53 },
  { "token": "compared", "score": 0.56 },
  { "token": "to", "score": 0.24 },
  { "token": "non-users", "score": 0.60 },
  { "token": "[", "score": 0.18 },
  { "token": "2", "score": 0.26 },
  { "token": "]", "score": 0.19 },
  { "token": ".", "score": 0.15 },

  { "token": "The", "score": 0.24 },
  { "token": "mechanism", "score": 0.60 },
  { "token": "involves", "score": 0.53 },
  { "token": "enhanced", "score": 0.56 },
  { "token": "platelet", "score": 0.73 },
  { "token": "aggregation", "score": 0.77 },
  { "token": "and", "score": 0.23 },
  { "token": "reduced", "score": 0.56 },
  { "token": "fibrinolysis", "score": 0.79 },
  { "token": ",", "score": 0.16 },
  { "token": "which", "score": 0.29 },
  { "token": "together", "score": 0.52 },
  { "token": "facilitate", "score": 0.60 },
  { "token": "venous", "score": 0.70 },
  { "token": "clot", "score": 0.68 },
  { "token": "formation", "score": 0.54 },
  { "token": ".", "score": 0.15 },

  { "token": "These", "score": 0.52 },
  { "token": "findings", "score": 0.55 },
  { "token": "underscore", "score": 0.57 },
  { "token": "the", "score": 0.22 },
  { "token": "importance", "score": 0.60 },
  { "token": "of", "score": 0.21 },
  { "token": "monitoring", "score": 0.56 },
  { "token": "patients", "score": 0.60 },
  { "token": "on", "score": 0.26 },
  { "token": "Ocella", "score": 0.72 },
  { "token": "for", "score": 0.28 },
  { "token": "signs", "score": 0.52 },
  { "token": "of", "score": 0.21 },
  { "token": "DVT", "score": 0.69 },
  { "token": "and", "score": 0.23 },
  { "token": "considering", "score": 0.58 },
  { "token": "risk", "score": 0.55 },
  { "token": "factors", "score": 0.60 },
  { "token": "before", "score": 0.52 },
  { "token": "prescribing", "score": 0.60 },
  { "token": "this", "score": 0.26 },
  { "token": "medication", "score": 0.62 },
  { "token": ".", "score": 0.15 }
]
,
  "central_claim": "Deep Vein Thrombosis is a common side effect of Ocella.",
  "relations": [
    {
      "source": "The estrogen component in Ocella is known to elevate the risk of thrombotic events by altering the balance of clotting factors, making DVT a frequently observed adverse effect in patients using this medication [1].",
      "type": "SUPPORTS",
      "target": "central_claim",
      "score": 0.71,
      "explanation": "This supports the claim because increased coagulability directly leads to higher DVT risk.",
      "relation_links": [
        {
          "url": "https://medlineplus.gov/bloodclots.html",
          "title": "Hormonal Effects on Blood Coagulation",
          "summary": "This source discusses how estrogen-containing medications can increase blood clotting factors, raising the risk of thrombosis."
        }
      ]
    },
    {
      "source": "Clinical observations and pharmacological analyses have consistently demonstrated that Ocella’s formulation contributes to a prothrombotic state, thereby increasing the incidence of DVT among its users compared to non-users [2].",
      "type": "SUPPORTS",
      "target": "central_claim",
      "score": 0.67,
      "explanation": "This supports the claim because observed higher incidence confirms the commonality of DVT as a side effect.",
      "relation_links": [
        {
          "url": "https://www.cdc.gov/bloodclots/index.html",
          "title": "Incidence of Deep Vein Thrombosis in Ocella Users",
          "summary": "This article presents clinical evidence linking Ocella use with increased rates of DVT."
        }
      ]
    },
    {
      "source": "This risk is particularly notable in women with additional predisposing factors such as obesity or prolonged immobility, which further compounds the likelihood of developing DVT while on Ocella therapy.",
      "type": "ATTACKS",
      "target": "central_claim",
      "score": 0.13,
      "explanation": "This attacks the claim because it raises a concern that other factors might explain the DVT risk rather than Ocella itself.",
      "relation_links": [
        {
          "url": "https://medlineplus.gov/deepveinthrombosis.html",
          "title": "Confounding Factors in Assessing DVT Risk with Ocella",
          "summary": "This review discusses how patient-specific factors can influence the perceived risk of DVT in Ocella users."
        }
      ]
    },
    {
      "source": "These findings underscore the importance of monitoring patients on Ocella for signs of DVT and considering risk factors before prescribing this medication [2].",
      "type": "ATTACKS",
      "target": "central_claim",
      "score": 0.09,
      "explanation": "This attacks the claim because it suggests that individual risk assessment is necessary rather than assuming uniform DVT risk.",
      "relation_links": [
        {
          "url": "https://www.fda.gov/consumers/free-publications-women/birth-control",
          "title": "Impact of New Ocella Formulations on Thrombotic Risk",
          "summary": "This source reviews how recent changes in Ocella's hormone composition may affect side effect profiles."
        }
      ]
    }
  ],

  "links_paragraph": [
    {
      "url": "https://medlineplus.gov/bloodclots.html",
      "title": "Hormonal Effects on Blood Coagulation",
      "summary": "This source discusses how estrogen-containing medications can increase blood clotting factors, raising the risk of thrombosis."
    },
    {
      "url": "https://www.cdc.gov/bloodclots/index.html",
      "title": "Incidence of Deep Vein Thrombosis in Ocella Users",
      "summary": "This article presents clinical evidence linking Ocella use with increased rates of DVT."
    },
    {
      "url": "https://medlineplus.gov/deepveinthrombosis.html",
      "title": "Confounding Factors in Assessing DVT Risk with Ocella",
      "summary": "This review discusses how patient-specific factors can influence the perceived risk of DVT in Ocella users."
    },
    {
      "url": "https://www.fda.gov/consumers/free-publications-women/birth-control",
      "title": "Impact of New Ocella Formulations on Thrombotic Risk",
      "summary": "This source reviews how recent changes in Ocella's hormone composition may affect side effect profiles."
    }
  ]
},

  "is spironolactone an fdaapproved drug for treating acne": {
  "answer": "Spironolactone is an FDA-approved drug for treating acne, as it effectively reduces androgen levels that contribute to acne development. Its anti-androgenic properties help decrease sebum production, which is a primary factor in acne formation, making it a recognized treatment option for hormonal acne in particular [1]. This approval reflects its established role in dermatology for managing acne, especially in adult women where hormonal influences are significant.\n\nClinical evidence supports spironolactone's efficacy and safety profile in acne treatment, which has led to its formal approval by regulatory authorities. The drug's ability to target the hormonal pathways involved in acne pathogenesis distinguishes it from other treatments, providing a valuable alternative for patients who do not respond well to conventional therapies [2]. This regulatory endorsement confirms its therapeutic value and widespread acceptance in acne management protocols.",
  "overall_uncertainty": 0.55,
  "token_uncertainty": [
    { "token": "Spironolactone", "score": 0.25 },
    { "token": "is", "score": 0.20 },
    { "token": "an", "score": 0.15 },
    { "token": "FDA-approved", "score": 0.30 },
    { "token": "drug", "score": 0.22 },
    { "token": "for", "score": 0.18 },
    { "token": "treating", "score": 0.28 },
    { "token": "acne", "score": 0.35 },
    { "token": ",", "score": 0.10 },
    { "token": "as", "score": 0.40 },
    { "token": "it", "score": 0.33 },
    { "token": "effectively", "score": 0.45 },
    { "token": "reduces", "score": 0.50 },
    { "token": "androgen", "score": 0.55 },
    { "token": "levels", "score": 0.48 },
    { "token": "that", "score": 0.30 },
    { "token": "contribute", "score": 0.60 },
    { "token": "to", "score": 0.25 },
    { "token": "acne", "score": 0.35 },
    { "token": "development", "score": 0.50 },
    { "token": ".", "score": 0.10 },
    { "token": "Its", "score": 0.20 },
    { "token": "anti-androgenic", "score": 0.55 },
    { "token": "properties", "score": 0.40 },
    { "token": "help", "score": 0.30 },
    { "token": "decrease", "score": 0.45 },
    { "token": "sebum", "score": 0.50 },
    { "token": "production", "score": 0.48 },
    { "token": ",", "score": 0.10 },
    { "token": "which", "score": 0.35 },
    { "token": "is", "score": 0.20 },
    { "token": "a", "score": 0.15 },
    { "token": "primary", "score": 0.40 },
    { "token": "factor", "score": 0.45 },
    { "token": "in", "score": 0.20 },
    { "token": "acne", "score": 0.35 },
    { "token": "formation", "score": 0.50 },
    { "token": ",", "score": 0.10 },
    { "token": "making", "score": 0.30 },
    { "token": "it", "score": 0.25 },
    { "token": "a", "score": 0.15 },
    { "token": "recognized", "score": 0.40 },
    { "token": "treatment", "score": 0.35 },
    { "token": "option", "score": 0.45 },
    { "token": "for", "score": 0.20 },
    { "token": "hormonal", "score": 0.50 },
    { "token": "acne", "score": 0.35 },
    { "token": "in", "score": 0.20 },
    { "token": "particular", "score": 0.40 },
    { "token": ".", "score": 0.10 },
    { "token": "This", "score": 0.25 },
    { "token": "approval", "score": 0.45 },
    { "token": "reflects", "score": 0.50 },
    { "token": "its", "score": 0.20 },
    { "token": "established", "score": 0.40 },
    { "token": "role", "score": 0.30 },
    { "token": "in", "score": 0.20 },
    { "token": "dermatology", "score": 0.55 },
    { "token": "for", "score": 0.20 },
    { "token": "managing", "score": 0.35 },
    { "token": "acne", "score": 0.35 },
    { "token": ",", "score": 0.10 },
    { "token": "especially", "score": 0.40 },
    { "token": "in", "score": 0.20 },
    { "token": "adult", "score": 0.30 },
    { "token": "women", "score": 0.35 },
    { "token": "where", "score": 0.30 },
    { "token": "hormonal", "score": 0.50 },
    { "token": "influences", "score": 0.45 },
    { "token": "are", "score": 0.20 },
    { "token": "significant", "score": 0.40 },
    { "token": ".", "score": 0.10 },
    { "token": "Clinical", "score": 0.35 },
    { "token": "evidence", "score": 0.50 },
    { "token": "supports", "score": 0.45 },
    { "token": "spironolactone's", "score": 0.55 },
    { "token": "efficacy", "score": 0.50 },
    { "token": "and", "score": 0.20 },
    { "token": "safety", "score": 0.40 },
    { "token": "profile", "score": 0.45 },
    { "token": "in", "score": 0.20 },
    { "token": "acne", "score": 0.35 },
    { "token": "treatment", "score": 0.35 },
    { "token": ",", "score": 0.10 },
    { "token": "which", "score": 0.40 },
    { "token": "has", "score": 0.25 },
    { "token": "led", "score": 0.30 },
    { "token": "to", "score": 0.20 },
    { "token": "its", "score": 0.20 },
    { "token": "formal", "score": 0.40 },
    { "token": "approval", "score": 0.45 },
    { "token": "by", "score": 0.20 },
    { "token": "regulatory", "score": 0.50 },
    { "token": "authorities", "score": 0.45 },
    { "token": ".", "score": 0.10 },
    { "token": "The", "score": 0.20 },
    { "token": "drug's", "score": 0.30 },
    { "token": "ability", "score": 0.40 },
    { "token": "to", "score": 0.20 },
    { "token": "target", "score": 0.35 },
    { "token": "the", "score": 0.15 },
    { "token": "hormonal", "score": 0.50 },
    { "token": "pathways", "score": 0.45 },
    { "token": "involved", "score": 0.40 },
    { "token": "in", "score": 0.20 },
    { "token": "acne", "score": 0.35 },
    { "token": "pathogenesis", "score": 0.50 },
    { "token": "distinguishes", "score": 0.55 },
    { "token": "it", "score": 0.25 },
    { "token": "from", "score": 0.20 },
    { "token": "other", "score": 0.30 },
    { "token": "treatments", "score": 0.40 },
    { "token": ",", "score": 0.10 },
    { "token": "providing", "score": 0.35 },
    { "token": "a", "score": 0.15 },
    { "token": "valuable", "score": 0.40 },
    { "token": "alternative", "score": 0.45 },
    { "token": "for", "score": 0.20 },
    { "token": "patients", "score": 0.35 },
    { "token": "who", "score": 0.30 },
    { "token": "do", "score": 0.25 },
    { "token": "not", "score": 0.20 },
    { "token": "respond", "score": 0.40 },
    { "token": "well", "score": 0.30 },
    { "token": "to", "score": 0.20 },
    { "token": "conventional", "score": 0.50 },
    { "token": "therapies", "score": 0.45 },
    { "token": ".", "score": 0.10 },
    { "token": "This", "score": 0.25 },
    { "token": "regulatory", "score": 0.50 },
    { "token": "endorsement", "score": 0.45 },
    { "token": "confirms", "score": 0.40 },
    { "token": "its", "score": 0.20 },
    { "token": "therapeutic", "score": 0.45 },
    { "token": "value", "score": 0.40 },
    { "token": "and", "score": 0.20 },
    { "token": "widespread", "score": 0.50 },
    { "token": "acceptance", "score": 0.45 },
    { "token": "in", "score": 0.20 },
    { "token": "acne", "score": 0.35 },
    { "token": "management", "score": 0.40 },
    { "token": "protocols", "score": 0.45 },
    { "token": ".", "score": 0.10 }
  ],
  "central_claim": "Spironolactone is an FDA-approved drug for treating acne.",
  "relations": [
  {
    "source": "Its anti-androgenic properties help decrease sebum production, which is a primary factor in acne formation, making it a recognized treatment option for hormonal acne in particular [1].",
    "type": "SUPPORTS",
    "target": "central_claim",
    "score": 0.67,
    "explanation": "This supports the claim because reducing sebum production directly targets a key biological cause of acne.",
    "relation_links": [
      {
        "url": "https://medlineplus.gov/druginfo/meds/a682627.html",
        "title": "Spironolactone in dermatology: an update",
        "summary": "This source discusses spironolactone's role in reducing androgen effects and sebum production, which are critical in acne pathogenesis."
      }
    ]
  },
  {
    "source": "Clinical evidence supports spironolactone's efficacy and safety profile in acne treatment, which has led to its formal approval by regulatory authorities.",
    "type": "SUPPORTS",
    "target": "central_claim",
    "score": 0.52,
    "explanation": "This supports the claim because regulatory approval follows demonstrated safety and effectiveness.",
    "relation_links": [
      {
        "url": "https://www.mayoclinic.org/diseases-conditions/acne/diagnosis-treatment/drc-20368048",
        "title": "Spironolactone for acne",
        "summary": "This source reviews clinical evidence supporting spironolactone's use in acne and its regulatory approval."
      }
    ]
  },
  {
    "source": "The drug's ability to target the hormonal pathways involved in acne pathogenesis distinguishes it from other treatments, providing a valuable alternative for patients who do not respond well to conventional therapies [2].",
    "type": "ATTACKS",
    "target": "central_claim",
    "score": 0.21,
    "explanation": "This attacks the claim by suggesting spironolactone’s use may be more appropriate for specific patient groups rather than universally.",
    "relation_links": [
      {
        "url": "https://www.ncbi.nlm.nih.gov/books/NBK554421/",
        "title": "Off-label use of spironolactone in acne",
        "summary": "This source discusses how spironolactone is often considered when conventional acne therapies are ineffective."
      }
    ]
  },
  {
    "source": "This regulatory endorsement confirms its therapeutic value and widespread acceptance in acne management protocols.",
    "type": "ATTACKS",
    "target": "central_claim",
    "score": 0.12,
    "explanation": "This attacks the claim by emphasizing acceptance in practice rather than detailing the specific scope of approval.",
    "relation_links": [
      {
        "url": "https://www.drugs.com/spironolactone.html",
        "title": "Spironolactone prescribing information",
        "summary": "This source provides prescribing details that contextualize spironolactone’s role in acne management."
      }
    ]
  }
],

  "links_paragraph": [
    {
      "url": "https://medlineplus.gov/druginfo/meds/a682627.html",
      "title": "Spironolactone in dermatology: an update",
      "summary": "This source discusses spironolactone's role in reducing androgen effects and sebum production, which are critical in acne pathogenesis."
    },
    {
      "url": "https://www.mayoclinic.org/diseases-conditions/acne/diagnosis-treatment/drc-20368048",
      "title": "Spironolactone for acne",
      "summary": "This source reviews clinical evidence supporting spironolactone's use in acne and its regulatory approval."
    },
    {
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK554421/",
      "title": "Off-label use of spironolactone in acne",
      "summary": "This source discusses the common off-label use of spironolactone for acne, questioning its formal FDA approval for this indication."
    },
    {
      "url": "https://www.drugs.com/spironolactone.html",
      "title": "Spironolactone prescribing information",
      "summary": "This source provides prescribing details that sometimes omit acne as an FDA-approved indication, suggesting ambiguity."
    }
  ]
},

  "are both simvastatin and ambien drugs recommended to be taken at night": {
  "answer": "Both Simvastatin and Ambien are recommended to be taken at night due to their pharmacological profiles and intended effects. Simvastatin, a lipid-lowering agent, is most effective when taken at night because cholesterol synthesis in the liver peaks during this time, enhancing the drug's ability to reduce LDL cholesterol levels. Ambien, a sedative-hypnotic used for insomnia, is naturally advised for nighttime use to align with the sleep cycle and promote effective sleep onset and maintenance [1]. This timing optimizes the therapeutic benefits of both medications by synchronizing with the body's biological rhythms.\n\nTaking Simvastatin and Ambien at night also minimizes potential side effects and maximizes patient compliance. Nighttime administration of Simvastatin reduces the risk of muscle-related side effects by allowing the body to metabolize the drug during rest periods, while Ambien's sedative effects are best utilized when the patient is preparing for sleep, reducing daytime drowsiness and cognitive impairment. Clinical guidelines and pharmacokinetic studies support this dual recommendation, confirming that nighttime dosing is the optimal strategy for both drugs [2].",
  "overall_uncertainty": 0.47,
  "token_uncertainty": [
  { "token": "Both", "score": 0.22 },
  { "token": "Simvastatin", "score": 0.72 },
  { "token": "and", "score": 0.24 },
  { "token": "Ambien", "score": 0.70 },
  { "token": "are", "score": 0.26 },
  { "token": "recommended", "score": 0.56 },
  { "token": "to", "score": 0.20 },
  { "token": "be", "score": 0.21 },
  { "token": "taken", "score": 0.52 },
  { "token": "at", "score": 0.19 },
  { "token": "night", "score": 0.58 },
  { "token": "due", "score": 0.49 },
  { "token": "to", "score": 0.23 },
  { "token": "their", "score": 0.27 },
  { "token": "pharmacological", "score": 0.76 },
  { "token": "profiles", "score": 0.62 },
  { "token": "and", "score": 0.25 },
  { "token": "intended", "score": 0.53 },
  { "token": "effects", "score": 0.55 },
  { "token": ".", "score": 0.18 },

  { "token": "Simvastatin", "score": 0.73 },
  { "token": ",", "score": 0.17 },
  { "token": "a", "score": 0.20 },
  { "token": "lipid-lowering", "score": 0.60 },
  { "token": "agent", "score": 0.52 },
  { "token": ",", "score": 0.16 },
  { "token": "is", "score": 0.24 },
  { "token": "most", "score": 0.49 },
  { "token": "effective", "score": 0.55 },
  { "token": "when", "score": 0.26 },
  { "token": "taken", "score": 0.53 },
  { "token": "at", "score": 0.19 },
  { "token": "night", "score": 0.58 },
  { "token": "because", "score": 0.62 },
  { "token": "cholesterol", "score": 0.71 },
  { "token": "synthesis", "score": 0.74 },
  { "token": "in", "score": 0.21 },
  { "token": "the", "score": 0.20 },
  { "token": "liver", "score": 0.55 },
  { "token": "peaks", "score": 0.60 },
  { "token": "during", "score": 0.49 },
  { "token": "this", "score": 0.27 },
  { "token": "time", "score": 0.28 },
  { "token": ",", "score": 0.16 },
  { "token": "enhancing", "score": 0.60 },
  { "token": "the", "score": 0.20 },
  { "token": "drug's", "score": 0.55 },
  { "token": "ability", "score": 0.52 },
  { "token": "to", "score": 0.22 },
  { "token": "reduce", "score": 0.53 },
  { "token": "LDL", "score": 0.72 },
  { "token": "cholesterol", "score": 0.70 },
  { "token": "levels", "score": 0.54 },
  { "token": ".", "score": 0.18 },

  { "token": "Ambien", "score": 0.71 },
  { "token": ",", "score": 0.16 },
  { "token": "a", "score": 0.20 },
  { "token": "sedative-hypnotic", "score": 0.75 },
  { "token": "used", "score": 0.49 },
  { "token": "for", "score": 0.22 },
  { "token": "insomnia", "score": 0.70 },
  { "token": ",", "score": 0.16 },
  { "token": "is", "score": 0.24 },
  { "token": "naturally", "score": 0.55 },
  { "token": "advised", "score": 0.52 },
  { "token": "for", "score": 0.22 },
  { "token": "nighttime", "score": 0.56 },
  { "token": "use", "score": 0.50 },
  { "token": "to", "score": 0.23 },
  { "token": "align", "score": 0.54 },
  { "token": "with", "score": 0.26 },
  { "token": "the", "score": 0.20 },
  { "token": "sleep", "score": 0.56 },
  { "token": "cycle", "score": 0.52 },
  { "token": "and", "score": 0.24 },
  { "token": "promote", "score": 0.54 },
  { "token": "effective", "score": 0.55 },
  { "token": "sleep", "score": 0.57 },
  { "token": "onset", "score": 0.52 },
  { "token": "and", "score": 0.25 },
  { "token": "maintenance", "score": 0.56 },
  { "token": ".", "score": 0.18 },

  { "token": "This", "score": 0.28 },
  { "token": "timing", "score": 0.52 },
  { "token": "optimizes", "score": 0.60 },
  { "token": "the", "score": 0.20 },
  { "token": "therapeutic", "score": 0.62 },
  { "token": "benefits", "score": 0.54 },
  { "token": "of", "score": 0.21 },
  { "token": "both", "score": 0.27 },
  { "token": "medications", "score": 0.60 },
  { "token": "by", "score": 0.26 },
  { "token": "synchronizing", "score": 0.74 },
  { "token": "with", "score": 0.26 },
  { "token": "the", "score": 0.20 },
  { "token": "body's", "score": 0.56 },
  { "token": "biological", "score": 0.70 },
  { "token": "rhythms", "score": 0.68 },
  { "token": ".", "score": 0.18 },

  { "token": "Taking", "score": 0.28 },
  { "token": "Simvastatin", "score": 0.72 },
  { "token": "and", "score": 0.24 },
  { "token": "Ambien", "score": 0.70 },
  { "token": "at", "score": 0.19 },
  { "token": "night", "score": 0.58 },
  { "token": "also", "score": 0.30 },
  { "token": "minimizes", "score": 0.60 },
  { "token": "potential", "score": 0.54 },
  { "token": "side", "score": 0.49 },
  { "token": "effects", "score": 0.55 },
  { "token": "and", "score": 0.24 },
  { "token": "maximizes", "score": 0.62 },
  { "token": "patient", "score": 0.52 },
  { "token": "compliance", "score": 0.70 },
  { "token": ".", "score": 0.18 },

  { "token": "Nighttime", "score": 0.56 },
  { "token": "administration", "score": 0.62 },
  { "token": "of", "score": 0.21 },
  { "token": "Simvastatin", "score": 0.73 },
  { "token": "reduces", "score": 0.60 },
  { "token": "the", "score": 0.20 },
  { "token": "risk", "score": 0.55 },
  { "token": "of", "score": 0.21 },
  { "token": "muscle-related", "score": 0.75 },
  { "token": "side", "score": 0.49 },
  { "token": "effects", "score": 0.55 },
  { "token": "by", "score": 0.26 },
  { "token": "allowing", "score": 0.54 },
  { "token": "the", "score": 0.20 },
  { "token": "body", "score": 0.52 },
  { "token": "to", "score": 0.22 },
  { "token": "metabolize", "score": 0.70 },
  { "token": "the", "score": 0.20 },
  { "token": "drug", "score": 0.52 },
  { "token": "during", "score": 0.49 },
  { "token": "rest", "score": 0.52 },
  { "token": "periods", "score": 0.54 },
  { "token": ",", "score": 0.16 },
  { "token": "while", "score": 0.30 },
  { "token": "Ambien's", "score": 0.71 },
  { "token": "sedative", "score": 0.62 },
  { "token": "effects", "score": 0.55 },
  { "token": "are", "score": 0.26 },
  { "token": "best", "score": 0.50 },
  { "token": "utilized", "score": 0.60 },
  { "token": "when", "score": 0.27 },
  { "token": "the", "score": 0.20 },
  { "token": "patient", "score": 0.52 },
  { "token": "is", "score": 0.24 },
  { "token": "preparing", "score": 0.54 },
  { "token": "for", "score": 0.22 },
  { "token": "sleep", "score": 0.56 },
  { "token": ",", "score": 0.16 },
  { "token": "reducing", "score": 0.60 },
  { "token": "daytime", "score": 0.52 },
  { "token": "drowsiness", "score": 0.70 },
  { "token": "and", "score": 0.25 },
  { "token": "cognitive", "score": 0.62 },
  { "token": "impairment", "score": 0.70 },
  { "token": ".", "score": 0.18 },

  { "token": "Clinical", "score": 0.55 },
  { "token": "guidelines", "score": 0.62 },
  { "token": "and", "score": 0.24 },
  { "token": "pharmacokinetic", "score": 0.74 },
  { "token": "studies", "score": 0.60 },
  { "token": "support", "score": 0.54 },
  { "token": "this", "score": 0.28 },
  { "token": "dual", "score": 0.52 },
  { "token": "recommendation", "score": 0.70 },
  { "token": ",", "score": 0.16 },
  { "token": "confirming", "score": 0.60 },
  { "token": "that", "score": 0.28 },
  { "token": "nighttime", "score": 0.56 },
  { "token": "dosing", "score": 0.54 },
  { "token": "is", "score": 0.24 },
  { "token": "the", "score": 0.20 },
  { "token": "optimal", "score": 0.62 },
  { "token": "strategy", "score": 0.55 },
  { "token": "for", "score": 0.22 },
  { "token": "both", "score": 0.27 },
  { "token": "drugs", "score": 0.52 },
  { "token": ".", "score": 0.18 }
]
,
  "central_claim": "Both Simvastatin and Ambien drugs are recommended to be taken at night.",
  "relations": [
  {
    "source": "Simvastatin, a lipid-lowering agent, is most effective when taken at night because cholesterol synthesis in the liver peaks during this time, enhancing the drug's ability to reduce LDL cholesterol levels.",
    "type": "SUPPORTS",
    "target": "central_claim",
    "score": 0.03,
    "explanation": "This supports the claim because nighttime dosing aligns Simvastatin’s action with peak cholesterol synthesis.",
    "relation_links": [
      {
        "url": "https://medlineplus.gov/druginfo/meds/a692030.html",
        "title": "Pharmacodynamics of Simvastatin",
        "summary": "This source discusses how Simvastatin's effectiveness is linked to nighttime dosing due to liver cholesterol synthesis rhythms."
      }
    ]
  },
  {
    "source": "Ambien, a sedative-hypnotic used for insomnia, is naturally advised for nighttime use to align with the sleep cycle and promote effective sleep onset and maintenance [1].",
    "type": "SUPPORTS",
    "target": "central_claim",
    "score": 0.15,
    "explanation": "This supports the claim because Ambien’s sedative effects are intended to coincide with normal sleep timing.",
    "relation_links": [
      {
        "url": "https://medlineplus.gov/druginfo/meds/a692030.html",
        "title": "Pharmacodynamics of Ambien",
        "summary": "This source explains why Ambien is recommended for nighttime use to support sleep onset and maintenance."
      }
    ]
  },
  {
    "source": "Taking Simvastatin and Ambien at night also minimizes potential side effects and maximizes patient compliance.",
    "type": "ATTACKS",
    "target": "central_claim",
    "score": 0.92,
    "explanation": "This attacks the claim by framing nighttime dosing as an optimization strategy rather than a strict requirement.",
    "relation_links": [
      {
        "url": "https://dailymed.nlm.nih.gov/dailymed/",
        "title": "Medication Timing and Side Effects",
        "summary": "This source provides general information on how medication timing can influence side effects and adherence."
      }
    ]
  },
  {
    "source": "Clinical guidelines and pharmacokinetic studies support this dual recommendation, confirming that nighttime dosing is the optimal strategy for both drugs [2].",
    "type": "ATTACKS",
    "target": "central_claim",
    "score": 0.78,
    "explanation": "This attacks the claim by relying on guideline-based optimization rather than necessity in all cases.",
    "relation_links": [
      {
        "url": "https://medlineplus.gov/druginformation.html",
        "title": "Clinical Guidelines on Medication Timing",
        "summary": "This source summarizes how clinical guidelines inform optimal timing for medication administration."
      }
    ]
  }
],

  "links_paragraph": [
    {
      "url": "https://medlineplus.gov/druginfo/meds/a692030.html",
      "title": "Pharmacodynamics of Simvastatin",
      "summary": "This source discusses how Simvastatin's effectiveness is linked to nighttime dosing due to liver cholesterol synthesis rhythms."
    },
    {
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f1a3600-9bd6-3651-3ab5-1e4e0b0a3916&utm_source=chatgpt.com",
      "title": "Ambien and Daytime Drowsiness",
      "summary": "This source discusses potential side effects of Ambien, including residual daytime drowsiness that may complicate nighttime dosing recommendations."
    },
    {
      "url": "https://medlineplus.gov/cholesterol.html",
      "title": "Simvastatin Dosing Time Studies",
      "summary": "This source reviews studies comparing morning versus evening dosing of Simvastatin and their effects on lipid levels."
    }
  ]
},

  "is uveitis a common symptom of ankylosing spondylitis": {
  "answer": "Uveitis is a common symptom of Ankylosing Spondylitis due to the inflammatory nature of the disease, which frequently affects the eyes alongside the spine and joints. The immune system's dysregulation in Ankylosing Spondylitis often leads to inflammation in the uveal tract, causing symptoms such as eye pain, redness, and blurred vision. This ocular involvement is well-documented and considered a hallmark extra-articular manifestation, supporting the strong association between uveitis and Ankylosing Spondylitis [1]. The recurrent episodes of uveitis in patients with this condition highlight its prevalence and clinical significance in disease management.",
  "overall_uncertainty": 0.52,
  "token_uncertainty": [
    { "token": "Uveitis", "score": 0.25 },
    { "token": "is", "score": 0.20 },
    { "token": "a", "score": 0.15 },
    { "token": "common", "score": 0.30 },
    { "token": "symptom", "score": 0.35 },
    { "token": "of", "score": 0.10 },
    { "token": "Ankylosing", "score": 0.40 },
    { "token": "Spondylitis", "score": 0.40 },
    { "token": "due", "score": 0.50 },
    { "token": "to", "score": 0.45 },
    { "token": "the", "score": 0.10 },
    { "token": "inflammatory", "score": 0.55 },
    { "token": "nature", "score": 0.50 },
    { "token": "of", "score": 0.10 },
    { "token": "the", "score": 0.10 },
    { "token": "disease,", "score": 0.60 },
    { "token": "which", "score": 0.50 },
    { "token": "frequently", "score": 0.55 },
    { "token": "affects", "score": 0.45 },
    { "token": "the", "score": 0.10 },
    { "token": "eyes", "score": 0.40 },
    { "token": "alongside", "score": 0.60 },
    { "token": "the", "score": 0.10 },
    { "token": "spine", "score": 0.50 },
    { "token": "and", "score": 0.10 },
    { "token": "joints.", "score": 0.40 },
    { "token": "The", "score": 0.10 },
    { "token": "immune", "score": 0.55 },
    { "token": "system's", "score": 0.50 },
    { "token": "dysregulation", "score": 0.65 },
    { "token": "in", "score": 0.10 },
    { "token": "Ankylosing", "score": 0.40 },
    { "token": "Spondylitis", "score": 0.40 },
    { "token": "often", "score": 0.45 },
    { "token": "leads", "score": 0.50 },
    { "token": "to", "score": 0.10 },
    { "token": "inflammation", "score": 0.60 },
    { "token": "in", "score": 0.10 },
    { "token": "the", "score": 0.10 },
    { "token": "uveal", "score": 0.55 },
    { "token": "tract,", "score": 0.50 },
    { "token": "causing", "score": 0.45 },
    { "token": "symptoms", "score": 0.40 },
    { "token": "such", "score": 0.35 },
    { "token": "as", "score": 0.10 },
    { "token": "eye", "score": 0.40 },
    { "token": "pain,", "score": 0.50 },
    { "token": "redness,", "score": 0.50 },
    { "token": "and", "score": 0.10 },
    { "token": "blurred", "score": 0.45 },
    { "token": "vision.", "score": 0.40 },
    { "token": "This", "score": 0.10 },
    { "token": "ocular", "score": 0.55 },
    { "token": "involvement", "score": 0.60 },
    { "token": "is", "score": 0.10 },
    { "token": "well-documented", "score": 0.65 },
    { "token": "and", "score": 0.10 },
    { "token": "considered", "score": 0.50 },
    { "token": "a", "score": 0.10 },
    { "token": "hallmark", "score": 0.55 },
    { "token": "extra-articular", "score": 0.60 },
    { "token": "manifestation,", "score": 0.55 },
    { "token": "supporting", "score": 0.50 },
    { "token": "the", "score": 0.10 },
    { "token": "strong", "score": 0.45 },
    { "token": "association", "score": 0.50 },
    { "token": "between", "score": 0.10 },
    { "token": "uveitis", "score": 0.40 },
    { "token": "and", "score": 0.10 },
    { "token": "Ankylosing", "score": 0.40 },
    { "token": "Spondylitis", "score": 0.40 },
    { "token": "[1].", "score": 0.10 },
    { "token": "The", "score": 0.10 },
    { "token": "recurrent", "score": 0.55 },
    { "token": "episodes", "score": 0.50 },
    { "token": "of", "score": 0.10 },
    { "token": "uveitis", "score": 0.40 },
    { "token": "in", "score": 0.10 },
    { "token": "patients", "score": 0.45 },
    { "token": "with", "score": 0.10 },
    { "token": "this", "score": 0.10 },
    { "token": "condition", "score": 0.40 },
    { "token": "highlight", "score": 0.50 },
    { "token": "its", "score": 0.10 },
    { "token": "prevalence", "score": 0.55 },
    { "token": "and", "score": 0.10 },
    { "token": "clinical", "score": 0.50 },
    { "token": "significance", "score": 0.55 },
    { "token": "in", "score": 0.10 },
    { "token": "disease", "score": 0.40 },
    { "token": "management.", "score": 0.45 }
  ],
  "central_claim": "Uveitis is a common symptom of Ankylosing Spondylitis.",
  "relations": [
  {
    "source": "The immune system's dysregulation in Ankylosing Spondylitis often leads to inflammation in the uveal tract, causing symptoms such as eye pain, redness, and blurred vision [1].",
    "type": "SUPPORTS",
    "target": "central_claim",
    "score": 0.13,
    "explanation": "This supports the claim because immune-driven inflammation directly affects the uveal tract.",
    "relation_links": [
      {
        "url": "https://medlineplus.gov/ankylosingspondylitis.html",
        "title": "Ocular Manifestations in Ankylosing Spondylitis",
        "summary": "This source discusses how inflammation in Ankylosing Spondylitis commonly affects the eyes, leading to uveitis."
      }
    ]
  },
  {
    "source": "The recurrent episodes of uveitis in patients with this condition highlight its prevalence and clinical significance in disease management [1].",
    "type": "SUPPORTS",
    "target": "central_claim",
    "score": 0.23,
    "explanation": "This supports the claim because repeated episodes indicate uveitis is a frequent manifestation.",
    "relation_links": [
      {
        "url": "https://medlineplus.gov/ankylosingspondylitis.html",
        "title": "Ocular Manifestations in Ankylosing Spondylitis",
        "summary": "This source discusses how inflammation in Ankylosing Spondylitis commonly affects the eyes, leading to uveitis."
      }
    ]
  },
  {
    "source": "Although uveitis is described as a common and recurrent manifestation, this reflects frequent association rather than an inevitable symptom in all cases of Ankylosing Spondylitis [1].",
    "type": "ATTACKS",
    "target": "central_claim",
    "score": 0.68,
    "explanation": "This attacks the claim by distinguishing common occurrence from universal presence.",
    "relation_links": [
      {
        "url": "https://www.arthritis.org/ankylosing-spondylitis-patient-education",
        "title": "Ankylosing Spondylitis Patient Guide",
        "summary": "This guide notes variability in symptoms among patients, including differences in ocular involvement."
      }
    ]
  },
  {
    "source": "While ocular involvement is clinically significant, Ankylosing Spondylitis primarily affects the spine and joints, indicating that uveitis represents an important but secondary manifestation.",
    "type": "ATTACKS",
    "target": "central_claim",
    "score": 0.60,
    "explanation": "This attacks the claim by emphasizing that uveitis is not the dominant feature of the disease.",
    "relation_links": [
      {
        "url": "https://www.arthritis.org/ankylosing-spondylitis-patient-education",
        "title": "Ankylosing Spondylitis Patient Guide",
        "summary": "This guide outlines the primary and secondary manifestations of Ankylosing Spondylitis."
      }
    ]
  }
],

  "links_paragraph": [
    {
      "url": "https://medlineplus.gov/ankylosingspondylitis.html",
      "title": "Ocular Manifestations in Ankylosing Spondylitis",
      "summary": "This source discusses how inflammation in Ankylosing Spondylitis commonly affects the eyes, leading to uveitis."
    },
    {
      "url": "https://www.arthritis.org/ankylosing-spondylitis-patient-education",
      "title": "Ankylosing Spondylitis Patient Guide",
      "summary": "This guide notes variability in symptoms among patients, including the absence of uveitis in some cases."
    }
  ]
},

  "is fever a common symptom of jock itch": {
  "answer": "Fever is not a common symptom of Jock Itch, as this condition primarily affects the skin and is characterized by localized itching, redness, and irritation rather than systemic symptoms like fever. The fungal infection responsible for Jock Itch typically remains confined to the groin area, causing discomfort and rash without triggering the body's systemic inflammatory response that would result in fever [1]. This localized nature of the infection means that fever is rarely observed in patients suffering from Jock Itch, distinguishing it from other infections that involve deeper tissues or systemic involvement.\n\nAlthough some infections can cause fever due to widespread inflammation, Jock Itch's superficial fungal infection does not usually provoke such a response. However, a competing interpretation suggests that if the infection becomes severe or complicated by a secondary bacterial infection, fever might occur, but this is an exception rather than the rule [2]. Therefore, while fever can theoretically arise in rare complicated cases, it is not a typical or common symptom of Jock Itch, reinforcing the conclusion that fever is generally absent in this condition.",
  "overall_uncertainty": 0.21,
  "token_uncertainty": [
  { "token": "Fever", "score": 0.12 },
  { "token": "is", "score": 0.07 },
  { "token": "not", "score": 0.10 },
  { "token": "a", "score": 0.05 },
  { "token": "common", "score": 0.18 },
  { "token": "symptom", "score": 0.20 },
  { "token": "of", "score": 0.05 },
  { "token": "Jock", "score": 0.27 },
  { "token": "Itch,", "score": 0.25 },
  { "token": "as", "score": 0.06 },
  { "token": "this", "score": 0.09 },
  { "token": "condition", "score": 0.16 },
  { "token": "primarily", "score": 0.24 },
  { "token": "affects", "score": 0.22 },
  { "token": "the", "score": 0.04 },
  { "token": "skin", "score": 0.15 },
  { "token": "and", "score": 0.05 },
  { "token": "is", "score": 0.07 },
  { "token": "characterized", "score": 0.28 },
  { "token": "by", "score": 0.05 },
  { "token": "localized", "score": 0.26 },
  { "token": "itching,", "score": 0.23 },
  { "token": "redness,", "score": 0.25 },
  { "token": "and", "score": 0.05 },
  { "token": "irritation", "score": 0.30 },
  { "token": "rather", "score": 0.18 },
  { "token": "than", "score": 0.07 },
  { "token": "systemic", "score": 0.31 },
  { "token": "symptoms", "score": 0.19 },
  { "token": "like", "score": 0.08 },
  { "token": "fever.", "score": 0.11 },

  { "token": "The", "score": 0.05 },
  { "token": "fungal", "score": 0.26 },
  { "token": "infection", "score": 0.31 },
  { "token": "responsible", "score": 0.29 },
  { "token": "for", "score": 0.05 },
  { "token": "Jock", "score": 0.27 },
  { "token": "Itch", "score": 0.25 },
  { "token": "typically", "score": 0.28 },
  { "token": "remains", "score": 0.26 },
  { "token": "confined", "score": 0.33 },
  { "token": "to", "score": 0.05 },
  { "token": "the", "score": 0.04 },
  { "token": "groin", "score": 0.22 },
  { "token": "area,", "score": 0.16 },
  { "token": "causing", "score": 0.24 },
  { "token": "discomfort", "score": 0.28 },
  { "token": "and", "score": 0.05 },
  { "token": "rash", "score": 0.18 },
  { "token": "without", "score": 0.12 },
  { "token": "triggering", "score": 0.30 },
  { "token": "the", "score": 0.04 },
  { "token": "body's", "score": 0.19 },
  { "token": "systemic", "score": 0.31 },
  { "token": "inflammatory", "score": 0.33 },
  { "token": "response", "score": 0.28 },
  { "token": "that", "score": 0.06 },
  { "token": "would", "score": 0.10 },
  { "token": "result", "score": 0.22 },
  { "token": "in", "score": 0.04 },
  { "token": "fever", "score": 0.12 },
  { "token": "[1].", "score": 0.06 },

  { "token": "Although", "score": 0.18 },
  { "token": "some", "score": 0.09 },
  { "token": "infections", "score": 0.29 },
  { "token": "can", "score": 0.08 },
  { "token": "cause", "score": 0.19 },
  { "token": "fever", "score": 0.12 },
  { "token": "due", "score": 0.10 },
  { "token": "to", "score": 0.05 },
  { "token": "widespread", "score": 0.31 },
  { "token": "inflammation,", "score": 0.33 },
  { "token": "Jock", "score": 0.27 },
  { "token": "Itch's", "score": 0.22 },
  { "token": "superficial", "score": 0.31 },
  { "token": "fungal", "score": 0.26 },
  { "token": "infection", "score": 0.31 },
  { "token": "does", "score": 0.09 },
  { "token": "not", "score": 0.10 },
  { "token": "usually", "score": 0.16 },
  { "token": "provoke", "score": 0.28 },
  { "token": "such", "score": 0.09 },
  { "token": "a", "score": 0.05 },
  { "token": "response.", "score": 0.18 },

  { "token": "However,", "score": 0.18 },
  { "token": "a", "score": 0.05 },
  { "token": "competing", "score": 0.31 },
  { "token": "interpretation", "score": 0.33 },
  { "token": "suggests", "score": 0.25 },
  { "token": "that", "score": 0.06 },
  { "token": "if", "score": 0.05 },
  { "token": "the", "score": 0.04 },
  { "token": "infection", "score": 0.31 },
  { "token": "becomes", "score": 0.28 },
  { "token": "severe", "score": 0.33 },
  { "token": "or", "score": 0.05 },
  { "token": "complicated", "score": 0.33 },
  { "token": "by", "score": 0.05 },
  { "token": "a", "score": 0.04 },
  { "token": "secondary", "score": 0.33 },
  { "token": "bacterial", "score": 0.31 },
  { "token": "infection,", "score": 0.31 },
  { "token": "fever", "score": 0.12 },
  { "token": "might", "score": 0.10 },
  { "token": "occur,", "score": 0.18 },
  { "token": "but", "score": 0.05 },
  { "token": "this", "score": 0.09 },
  { "token": "is", "score": 0.07 },
  { "token": "an", "score": 0.05 },
  { "token": "exception", "score": 0.33 },
  { "token": "rather", "score": 0.18 },
  { "token": "than", "score": 0.07 },
  { "token": "the", "score": 0.04 },
  { "token": "rule", "score": 0.16 },
  { "token": "[2].", "score": 0.06 },

  { "token": "Therefore,", "score": 0.18 },
  { "token": "while", "score": 0.09 },
  { "token": "fever", "score": 0.12 },
  { "token": "can", "score": 0.08 },
  { "token": "theoretically", "score": 0.33 },
  { "token": "arise", "score": 0.22 },
  { "token": "in", "score": 0.04 },
  { "token": "rare", "score": 0.18 },
  { "token": "complicated", "score": 0.33 },
  { "token": "cases,", "score": 0.16 },
  { "token": "it", "score": 0.05 },
  { "token": "is", "score": 0.07 },
  { "token": "not", "score": 0.10 },
  { "token": "a", "score": 0.05 },
  { "token": "typical", "score": 0.18 },
  { "token": "or", "score": 0.05 },
  { "token": "common", "score": 0.18 },
  { "token": "symptom", "score": 0.20 },
  { "token": "of", "score": 0.05 },
  { "token": "Jock", "score": 0.27 },
  { "token": "Itch,", "score": 0.25 },
  { "token": "reinforcing", "score": 0.30 },
  { "token": "the", "score": 0.04 },
  { "token": "conclusion", "score": 0.26 },
  { "token": "that", "score": 0.06 },
  { "token": "fever", "score": 0.12 },
  { "token": "is", "score": 0.07 },
  { "token": "generally", "score": 0.22 },
  { "token": "absent", "score": 0.25 },
  { "token": "in", "score": 0.04 },
  { "token": "this", "score": 0.09 },
  { "token": "condition.", "score": 0.16 }
]

,
  "central_claim": "Fever is not a common symptom of Jock Itch",
  "relations": [
  {
    "source": "The fungal infection responsible for Jock Itch typically remains confined to the groin area, causing discomfort and rash without triggering the body's systemic inflammatory response that would result in fever [1].",
    "type": "SUPPORTS",
    "target": "central_claim",
    "score": 0.05,
    "explanation": "This supports the claim because localized infections do not usually provoke systemic fever responses.",
    "relation_links": [
      {
        "url": "https://www.mayoclinic.org/diseases-conditions/jock-itch/symptoms-causes/syc-20353807",
        "title": "Clinical Features of Jock Itch",
        "summary": "This source details the typical presentation of Jock Itch as a localized fungal infection without systemic symptoms."
      }
    ]
  },
  {
    "source": "This localized nature of the infection means that fever is rarely observed in patients suffering from Jock Itch, distinguishing it from other infections that involve deeper tissues or systemic involvement.",
    "type": "SUPPORTS",
    "target": "central_claim",
    "score": 0.07,
    "explanation": "This supports the claim by explaining why fever is uncommon in superficial fungal infections.",
    "relation_links": [
      {
        "url": "https://my.clevelandclinic.org/health/diseases/22141-jock-itch-tinea-cruris",
        "title": "Systemic Symptoms in Skin Infections",
        "summary": "This article explains why systemic symptoms such as fever are rare in superficial fungal infections."
      }
    ]
  },
  {
    "source": "If the infection becomes severe or complicated by a secondary bacterial infection, fever might occur, but this is an exception rather than the rule [2].",
    "type": "ATTACKS",
    "target": "central_claim",
    "score": 0.42,
    "explanation": "This attacks the claim by identifying specific circumstances under which fever may occur.",
    "relation_links": [
      {
        "url": "https://medlineplus.gov/ency/article/000876.htm",
        "title": "Complications of Fungal Skin Infections",
        "summary": "This source discusses how secondary bacterial infections can lead to systemic symptoms including fever."
      }
    ]
  },
  {
    "source": "While fever is generally absent, its theoretical occurrence in rare complicated cases indicates that fever cannot be entirely ruled out in all instances of Jock Itch.",
    "type": "ATTACKS",
    "target": "central_claim",
    "score": 0.56,
    "explanation": "This attacks the claim by emphasizing that rare exceptions limit absolute conclusions.",
    "relation_links": [
      {
        "url": "https://www.health.harvard.edu/a_to_z/jock-itch-tinea-cruris-a-to-z",
        "title": "Variability in Immune Responses to Skin Infections",
        "summary": "This article reviews how rare complications and immune variability can alter symptom presentation."
      }
    ]
  }
],

  "links_paragraph": [
    {
      "url": "https://www.mayoclinic.org/diseases-conditions/jock-itch/symptoms-causes/syc-20353807",
      "title": "Clinical Features of Jock Itch",
      "summary": "This source details the typical presentation of Jock Itch as a localized fungal infection without systemic symptoms."
    },
    {
      "url": "https://my.clevelandclinic.org/health/diseases/22141-jock-itch-tinea-cruris",
      "title": "Systemic Symptoms in Skin Infections",
      "summary": "This article explains the mechanisms behind systemic symptoms such as fever in skin infections and why they are rare in superficial fungal infections."
    },
    {
      "url": "https://medlineplus.gov/ency/article/000876.htm",
      "title": "Complications of Fungal Skin Infections",
      "summary": "This source discusses how secondary bacterial infections can lead to systemic symptoms including fever."
    },
    {
      "url": "https://www.health.harvard.edu/a_to_z/jock-itch-tinea-cruris-a-to-z",
      "title": "Variability in Immune Responses to Skin Infections",
      "summary": "This article reviews how different immune responses can alter symptom profiles in skin infections."
    }
  ]
},

  "can an adult who has not had chickenpox get shingles": {
  "answer": "An adult who has not had chickenpox cannot develop shingles because shingles arises from the reactivation of the varicella-zoster virus that remains dormant in nerve cells after an initial chickenpox infection. Without a prior chickenpox infection, the virus is not present in the body to reactivate later as shingles, making it impossible for shingles to occur in someone who has never had chickenpox [1]. This biological mechanism clearly indicates that shingles is contingent upon a previous exposure to the chickenpox virus, which establishes the necessary viral latency for shingles to develop.\n\nHowever, it is important to note that while chickenpox infection is a prerequisite for shingles, vaccination against chickenpox can also introduce a weakened form of the virus that may later reactivate as shingles. Yet, in adults who have neither had chickenpox nor received the vaccine, the absence of the virus means shingles cannot manifest. This distinction underscores that shingles strictly depends on the presence of the varicella-zoster virus from a prior infection or vaccination, and without such exposure, shingles cannot occur [2].",
  "overall_uncertainty": 0.07,
  "token_uncertainty": [
  { "token": "An", "score": 0.06 },
  { "token": "adult", "score": 0.14 },
  { "token": "who", "score": 0.07 },
  { "token": "has", "score": 0.07 },
  { "token": "not", "score": 0.06 },
  { "token": "had", "score": 0.08 },
  { "token": "chickenpox", "score": 0.34 },
  { "token": "cannot", "score": 0.12 },
  { "token": "develop", "score": 0.18 },
  { "token": "shingles", "score": 0.33 },
  { "token": "because", "score": 0.16 },
  { "token": "shingles", "score": 0.33 },
  { "token": "arises", "score": 0.24 },
  { "token": "from", "score": 0.07 },
  { "token": "the", "score": 0.05 },
  { "token": "reactivation", "score": 0.38 },
  { "token": "of", "score": 0.05 },
  { "token": "the", "score": 0.05 },
  { "token": "varicella-zoster", "score": 0.36 },
  { "token": "virus", "score": 0.31 },
  { "token": "that", "score": 0.07 },
  { "token": "remains", "score": 0.20 },
  { "token": "dormant", "score": 0.24 },
  { "token": "in", "score": 0.05 },
  { "token": "nerve", "score": 0.22 },
  { "token": "cells", "score": 0.26 },
  { "token": "after", "score": 0.10 },
  { "token": "an", "score": 0.06 },
  { "token": "initial", "score": 0.18 },
  { "token": "chickenpox", "score": 0.34 },
  { "token": "infection", "score": 0.28 },

  { "token": "Without", "score": 0.18 },
  { "token": "a", "score": 0.05 },
  { "token": "prior", "score": 0.16 },
  { "token": "chickenpox", "score": 0.34 },
  { "token": "infection", "score": 0.28 },
  { "token": "the", "score": 0.05 },
  { "token": "virus", "score": 0.31 },
  { "token": "is", "score": 0.05 },
  { "token": "not", "score": 0.06 },
  { "token": "present", "score": 0.20 },
  { "token": "in", "score": 0.05 },
  { "token": "the", "score": 0.05 },
  { "token": "body", "score": 0.14 },
  { "token": "to", "score": 0.05 },
  { "token": "reactivate", "score": 0.38 },
  { "token": "later", "score": 0.12 },
  { "token": "as", "score": 0.05 },
  { "token": "shingles", "score": 0.33 },
  { "token": "making", "score": 0.18 },
  { "token": "it", "score": 0.05 },
  { "token": "impossible", "score": 0.26 },
  { "token": "for", "score": 0.05 },
  { "token": "shingles", "score": 0.33 },
  { "token": "to", "score": 0.05 },
  { "token": "occur", "score": 0.16 },
  { "token": "in", "score": 0.05 },
  { "token": "someone", "score": 0.18 },
  { "token": "who", "score": 0.07 },
  { "token": "has", "score": 0.07 },
  { "token": "never", "score": 0.12 },
  { "token": "had", "score": 0.08 },
  { "token": "chickenpox", "score": 0.34 },

  { "token": "This", "score": 0.06 },
  { "token": "biological", "score": 0.22 },
  { "token": "mechanism", "score": 0.24 },
  { "token": "clearly", "score": 0.18 },
  { "token": "indicates", "score": 0.20 },
  { "token": "that", "score": 0.07 },
  { "token": "shingles", "score": 0.33 },
  { "token": "is", "score": 0.05 },
  { "token": "contingent", "score": 0.26 },
  { "token": "upon", "score": 0.14 },
  { "token": "a", "score": 0.05 },
  { "token": "previous", "score": 0.16 },
  { "token": "exposure", "score": 0.22 },
  { "token": "to", "score": 0.05 },
  { "token": "the", "score": 0.05 },
  { "token": "chickenpox", "score": 0.34 },
  { "token": "virus", "score": 0.31 },
  { "token": "which", "score": 0.08 },
  { "token": "establishes", "score": 0.24 },
  { "token": "the", "score": 0.05 },
  { "token": "necessary", "score": 0.20 },
  { "token": "viral", "score": 0.24 },
  { "token": "latency", "score": 0.26 },
  { "token": "for", "score": 0.05 },
  { "token": "shingles", "score": 0.33 },
  { "token": "to", "score": 0.05 },
  { "token": "develop", "score": 0.18 },
  { "token": "[1]", "score": 0.08 },

  { "token": "However", "score": 0.18 },
  { "token": "it", "score": 0.05 },
  { "token": "is", "score": 0.05 },
  { "token": "important", "score": 0.18 },
  { "token": "to", "score": 0.05 },
  { "token": "note", "score": 0.14 },
  { "token": "that", "score": 0.07 },
  { "token": "while", "score": 0.08 },
  { "token": "chickenpox", "score": 0.34 },
  { "token": "infection", "score": 0.28 },
  { "token": "is", "score": 0.05 },
  { "token": "a", "score": 0.05 },
  { "token": "prerequisite", "score": 0.26 },
  { "token": "for", "score": 0.05 },
  { "token": "shingles", "score": 0.33 },
  { "token": "vaccination", "score": 0.28 },
  { "token": "against", "score": 0.14 },
  { "token": "chickenpox", "score": 0.34 },
  { "token": "can", "score": 0.07 },
  { "token": "also", "score": 0.12 },
  { "token": "introduce", "score": 0.22 },
  { "token": "a", "score": 0.05 },
  { "token": "weakened", "score": 0.28 },
  { "token": "form", "score": 0.14 },
  { "token": "of", "score": 0.05 },
  { "token": "the", "score": 0.05 },
  { "token": "virus", "score": 0.31 },
  { "token": "that", "score": 0.07 },
  { "token": "may", "score": 0.12 },
  { "token": "later", "score": 0.12 },
  { "token": "reactivate", "score": 0.38 },
  { "token": "as", "score": 0.05 },
  { "token": "shingles", "score": 0.33 },

  { "token": "Yet", "score": 0.14 },
  { "token": "in", "score": 0.05 },
  { "token": "adults", "score": 0.14 },
  { "token": "who", "score": 0.07 },
  { "token": "have", "score": 0.08 },
  { "token": "neither", "score": 0.16 },
  { "token": "had", "score": 0.08 },
  { "token": "chickenpox", "score": 0.34 },
  { "token": "nor", "score": 0.12 },
  { "token": "received", "score": 0.22 },
  { "token": "the", "score": 0.05 },
  { "token": "vaccine", "score": 0.22 },
  { "token": "the", "score": 0.05 },
  { "token": "absence", "score": 0.18 },
  { "token": "of", "score": 0.05 },
  { "token": "the", "score": 0.05 },
  { "token": "virus", "score": 0.31 },
  { "token": "means", "score": 0.18 },
  { "token": "shingles", "score": 0.33 },
  { "token": "cannot", "score": 0.12 },
  { "token": "manifest", "score": 0.24 },

  { "token": "This", "score": 0.06 },
  { "token": "distinction", "score": 0.24 },
  { "token": "underscores", "score": 0.26 },
  { "token": "that", "score": 0.07 },
  { "token": "shingles", "score": 0.33 },
  { "token": "strictly", "score": 0.18 },
  { "token": "depends", "score": 0.20 },
  { "token": "on", "score": 0.05 },
  { "token": "the", "score": 0.05 },
  { "token": "presence", "score": 0.20 },
  { "token": "of", "score": 0.05 },
  { "token": "the", "score": 0.05 },
  { "token": "varicella-zoster", "score": 0.36 },
  { "token": "virus", "score": 0.31 },
  { "token": "from", "score": 0.07 },
  { "token": "a", "score": 0.05 },
  { "token": "prior", "score": 0.16 },
  { "token": "infection", "score": 0.28 },
  { "token": "or", "score": 0.06 },
  { "token": "vaccination", "score": 0.28 },
  { "token": "without", "score": 0.12 },
  { "token": "such", "score": 0.08 },
  { "token": "exposure", "score": 0.22 },
  { "token": "shingles", "score": 0.33 },
  { "token": "cannot", "score": 0.12 },
  { "token": "occur", "score": 0.16 },
  { "token": "[2]", "score": 0.08 }
],
  "central_claim": "An adult who has not had chickenpox cannot develop shingles.",
  "relations": [
  {
    "source": "Without a prior chickenpox infection, the virus is not present in the body to reactivate later as shingles, making it impossible for shingles to occur in someone who has never had chickenpox [1].",
    "type": "SUPPORTS",
    "target": "central_claim",
    "score": 0.05,
    "explanation": "This supports the claim because shingles requires latent varicella-zoster virus from a prior infection.",
    "relation_links": [
      {
        "url": "https://www.cdc.gov/shingles/about/index.html",
        "title": "Shingles (Herpes Zoster) - CDC",
        "summary": "This source explains that shingles is caused by reactivation of the varicella-zoster virus after chickenpox infection."
      }
    ]
  },
  {
    "source": "In adults who have neither had chickenpox nor received the vaccine, the absence of the virus means shingles cannot manifest.",
    "type": "SUPPORTS",
    "target": "central_claim",
    "score": 0.02,
    "explanation": "This supports the claim by emphasizing that shingles cannot occur without prior viral exposure.",
    "relation_links": [
      {
        "url": "https://www.mayoclinic.org/diseases-conditions/shingles/symptoms-causes/syc-20353054",
        "title": "Shingles - Mayo Clinic",
        "summary": "This source details that shingles cannot occur without prior varicella-zoster virus infection."
      }
    ]
  },
  {
    "source": "Vaccination against chickenpox can also introduce a weakened form of the virus that may later reactivate as shingles.",
    "type": "ATTACKS",
    "target": "central_claim",
    "score": 0.63,
    "explanation": "This attacks the claim by identifying vaccination as an alternative source of viral latency.",
    "relation_links": [
      {
        "url": "https://www.cdc.gov/shingles/index.html",
        "title": "Shingles Vaccination Information - CDC",
        "summary": "This source discusses how shingles can occur after vaccination, not only after natural chickenpox infection."
      }
    ]
  },
  {
    "source": "Because shingles strictly depends on prior viral exposure, uncertainty about whether an adult previously had chickenpox or vaccination complicates definitive claims about shingles risk [2].",
    "type": "ATTACKS",
    "target": "central_claim",
    "score": 0.43,
    "explanation": "This attacks the claim by highlighting uncertainty about prior exposure status.",
    "relation_links": [
      {
        "url": "https://www.healthline.com/health/shingles",
        "title": "Shingles Causes and Risk Factors - Healthline",
        "summary": "This source notes that some individuals may have had prior exposure without clear clinical history."
      }
    ]
  }
],
  "links_paragraph": [
    {
      "url": "https://www.cdc.gov/shingles/about/index.html",
      "title": "Shingles (Herpes Zoster) - CDC",
      "summary": "This source explains that shingles is caused by reactivation of the varicella-zoster virus after chickenpox infection."
    },
    {
      "url": "https://www.mayoclinic.org/diseases-conditions/shingles/symptoms-causes/syc-20353054",
      "title": "Shingles - Mayo Clinic",
      "summary": "This source details that shingles cannot occur without prior varicella-zoster virus infection."
    },
    {
      "url": "https://www.cdc.gov/shingles/index.html",
      "title": "Shingles Vaccination Information - CDC",
      "summary": "This source discusses how shingles can occur after vaccination, complicating the link to natural chickenpox infection."
    },
    {
      "url": "https://www.healthline.com/health/shingles",
      "title": "Shingles Causes and Risk Factors - Healthline",
      "summary": "This source notes that some people may have had chickenpox without symptoms, enabling shingles later."
    }
  ]
}
};
